RxDoctor Payments Data

Larissa Camejo, MD

Ophthalmology · Palm Beach Gardens, FLNPI 1447286190

Payments from drug & device makers

$244,334in general payments, 2019–2025

Across 479 payments — averaging $510.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$80K
  • Aerie Pharmaceuticals, Inc.$64K
  • Sight Sciences, Inc.$24K
  • Nova Eye, Inc.$22K
  • Glaukos Corporation$14K
  • NEW World Medical,inc.$13K
  • plus $27K from 27 others

What the payments were for

  • Consulting fees$105,56943%
  • Speaking & faculty fees$100,77341%
  • Travel & lodging$19,2458%
  • Food & beverage$18,4268%
  • Education$2220%
  • Gifts$390%
  • Entertainment$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$244,334 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$373,874
Medicare patients
303
Services billed
2,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine120$114,099
XiidraLifitegrast81$77,340
RocklatanNetarsudil Mesylat/Latanoprost151$65,389
LumiganBimatoprost146$60,465
VyzultaLatanoprostene Bunod146$53,019
RhopressaNetarsudil Mesylate134$49,517
CombiganBrimonidine Tartrate/Timolol145$45,880
Alphagan PBrimonidine Tartrate111$28,552
IlevroNepafenac60$24,174
Prednisolone Acetate301$11,924
SimbrinzaBrinzolamide/Brimonidine Tart54$11,177
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol88$10,993
ProlensaBromfenac Sodium25$8,780
Brimonidine Tartrate395$8,064
Pilocarpine Hcl131$7,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$80,224$248,996522 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$1,268$130,358227 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$64,171$114,906285 claims
NovartisIlevro$262$24,17460 claims
AlconSimbrinza$10,703$11,17754 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$123$8,78025 claims
Thea Pharma Inc.Iyuzeh$324$6,58018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →